# US 2012/0252028 A1 · Target genes for cancer therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252028 A1
- Document ID: US20120252028A1
- Status: Published application
- Kind: A1
- Application number: 13/390,454
- Filed: 2010-08-16
- Published: 2012-10-04
- Earliest claimed: 2009-08-14
- Inventors: Michael Shtulman; Igor B. Roninson
- Web page: https://patentgrep.com/patent/US20120252028A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention provides new gene targets for cancer chemotherapy, their use in assays for identifying new small molecule cancer chemotherapeutic agents, methods for inhibiting cancer cell growth comprising contacting a cell with a gene expression blocking agent that inhibits the expression of such genes and methods for therapeutic treatment of cancer in a mammal, comprising administering to the mammal such a gene expression blocking agent. A preferred gene target is coatomer protein zeta-1 subunit (COPZ1).

## Claims

### Claim at position 1

1-10. (canceled)

### Claim 11

A method for selectively killing tumor cells comprising selectively inhibiting expression or function of coatomer protein zeta-1 subunit (COPZ1) gene or its encoded CopI-ζ1 protein, respectively.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the expression of COPZ1 is inhibited by an agent selected from an siRNA, an antisense oligonucleotide, and a ribozyme, wherein the agent selectively targets mRNA encoding CopI-ζ1 protein.

### Claim 13 (depends on 11)

The method according to claim 11, wherein the expression of COPZ1 is inhibited by a small molecule that selectively inhibits COPZ1 expression.

### Claim 14 (depends on 11)

The method according to claim 11, wherein the function of CopI-ζ1 protein is inhibited by a small molecule that inhibits CopI-ζ1 protein.

### Claim 15

A method for treating an individual having cancer, comprising selectively inhibiting in the individual expression or function of COPZ1 gene or its encoded CopI-ζ1 protein respectively.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the expression of COPZ1 is inhibited by an agent selected from an siRNA, an antisense oligonucleotide, and a ribozyme, wherein the agent selectively targets mRNA encoding CopI-ζ1 protein.

### Claim 17 (depends on 15)

The method according to claim 15, wherein the expression of COPZ1 is inhibited by a small molecule that selectively inhibits COPZ1 expression.

### Claim 18 (depends on 15)

The method according to claim 15, wherein the function of CopI-ζ1 protein is inhibited by a small molecule that inhibits CopI-ζ1 protein.

### Claim 19

(canceled)

### Claim 20

A method for identifying a selective small molecule inhibitor of cancer cell growth comprising:
(a) culturing a mammalian cell comprising a recombinant DNA construct comprising a first reporter gene operatively associated with a COPZ1 promoter and a second reporter gene operatively associated with a COPZ2 promoter in the presence of a test compound;
(b) culturing the mammalian cell in the absence of the test compound;
(c) assaying the cells from (a) and (b) for the expression or activity of the first reporter gene and the second reporter gene, or their encoded proteins; and
(d) identifying the test compound as a selective small molecule inhibitor of cancer cell growth if the expression or activity of the first reporter gene or its encoded protein is inhibited to a greater extent than the expression or activity of the second reporter gene or its encoded protein in cells cultured as in (a), but not in cells cultured as in (b).

### Claim at position 12

21-23. (canceled)

### Claim 24

A method for identifying a selective small molecule inhibitor of cancer cell growth comprising:
(a) providing purified CopI-ζ1 protein and purified CopI-γ protein in the presence of a test compound to allow an interaction of an assayable magnitude between the purified CopI-ζ1 protein and the purified CopI-γ protein;
(b) providing purified CopI-ζ1 protein and purified CopI-γ protein in the absence of the test compound to allow an interaction of an assayable magnitude between the purified CopI-ζ1 protein and the purified CopI-γ protein;
(c) providing purified CopI-ζ2 protein and purified CopI-γ protein in the presence of the test compound to allow an interaction of an assayable magnitude between the purified CopI-ζ2 protein and the purified CopI-γ protein;
(d) providing purified CopI-ζ2 protein and purified CopI-γ protein in the absence of the test compound to allow an interaction of an assayable magnitude between the purified CopI-ζ2 protein and the purified CopI-γ protein;
(e) assaying the magnitude of the interaction between purified CopI-ζ1 protein and purified CopI-ζ protein in steps (a) and (b);
(f) assaying the magnitude of the interaction between purified CopI-ζ2 protein and purified CopI-γ protein in steps (c) and (d); and
(g) identifying the test compound as a selective inhibitor of CopI-ζ1 protein if the magnitude of the interaction is lesser in step (a) than in step (c), but the magnitude of the interaction in step (b) is not lesser than the magnitude of the interaction in step (d).

### Claim 25 (depends on 24)

The method according to claim 24, wherein the purified CopI-ζ1 protein or the purified CopI-γ protein are labeled with a fluorophore suitable for fluorescence resonance energy transfer (FRET), the CopI-ζ2 protein or the purified CopI-γ protein are labeled with a fluorophore suitable for FRET, and the magnitude of the interactions are assayed by FRET.

### Claim at position 15

26-27. (canceled)
